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Abstract
Background: Patients with human immunodeficiency virus (HIV) infection are at risk for Mycobacterium tuberculosis
(TB) coinfection. The advent of antiretroviral therapy restores immunity in HIV-infected patients, but predisposes
patients to immune reconstitution inflammatory syndrome (IRIS).
Case Presentation: A 25-year-old HIV-infected male presented with fever, productive cough, and body weight loss
for 2 months. His CD4 cell count was 11 cells/μl and HIV-1 viral load was 315,939 copies/ml. Antituberculosis
therapy was initiated after the diagnosis of pulmonary TB. One week after antituberculosis therapy, antiretroviral
therapy was started. However, multiple mediastinal lymphadenopathies and chylothorax developed. Adequate
drainage of the chylothorax, suspension of antiretroviral therapy, and continued antituberculosis therapy resulted in
successful treatment and good outcome.
Conclusions: Chylothorax is a rare manifestation of TB-associated IRIS in HIV-infected patients. Careful monitoring
for development of IRIS during treatment of HIV-TB coinfection is essential to minimize the associated morbidity
and mortality.
Background
Patients with human immunodeficiency virus (HIV)
infection are at risk for coinfection with Mycobacterium
tuberculosis (TB) [1]. Highly active antiretroviral therapy
restores the immunity of HIV-infected patients, but
immune reconstitution inflammatory syndrome (IRIS)
may develop [2,3]. We report a case of HIV and TB
coinfection who developed chylothorax as a manifesta-
tion of IRIS after the initiation of antituberculosis and
antiretroviral therapy within a one-week interval.
Case Presenatation
A 25-year-old HIV-1-infected man presented with fever,
productive cough, and body weight loss for 2 months.
On admission, physical examination disclosed oral thrush
and inspiratory crackles over his lung fields bilaterally.
He had a CD4 cell count of 11 cells/μla n da nH I V - 1
viral load of 315,939 copies/ml. Chest X-ray revealed a
consolidation in his right lung and multiple nodular infil-
trations in the left lung field (Figure 1A). A sputum
smear was positive for acid-fast bacilli and the sputum
culture subsequently grew TB. He was treated with
rifampin, isoniazid, ethambutol, and pyrazinamide initi-
ally, and his fever subsided gradually. Due to a strikingly
low CD4 cell count, antiretroviral therapy with lamivu-
dine, didanosine, and efavirenz was begun 1 week after
starting antituberculosis chemotherapy. The patient
became febrile again 4 days after the start of antiretro-
viral therapy. IRIS was suspected. His fever persisted
despite prescription of oral prednisolone (1 mg/kg daily).
The patient then suffered from progressive dyspnea, and
a chest X-ray taken 3 weeks after starting the antiretro-
viral therapy demonstrated a massive, left-sided, pleural
effusion (Figure 1B). Antiretroviral therapy was withheld
in view of this potentially life-threatening manifestation
of IRIS. Computed tomography of the chest disclosed
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osteolytic lesions in the sternum, vertebra, and ribs. A
Tc-99m methylene diphosphonate whole body bone scan
showed multiple, increased radioactive lesions in his axial
and appendicular skeleton (Figure 1D). Numerous acid-
fast bacilli were found in a vertebral bone biopsy of T11.
A pigtail catheter was inserted into his left pleural cavity,
draining out a chylous effusion (Figure 1E). Pleural fluid
analysis showed: total protein, 5.6 g/dl; lactate dehydro-
genase, 154 IU/L; glucose, 100 mg/dl; total cholesterol,
66 mg/dl; and triglycerides, 1,230 mg/dl. Cytology of
the pleural effusion was negative for malignant cells and
cultures for bacteria, mycobacteria, and fungi were all
negative. With continued antituberculosis therapy, the
amount of chylous pleural effusion decreased. The drai-
nage tube was removed 3 weeks later, after draining a
total of 9,630 ml of chylous effusion. Corticosteroid
was administered for 2 months. Antiretroviral therapy
was re-started 1 month after removal of the drainage
tube, and no further symptoms of IRIS were observed.
The patient completed 12 months of antituberculosis
therapy (2 months of rifampin, isoniazid, ethambutol,
and pyrazinamide; 10 months of rifampin and isoniazid).
There were no symptoms of relapse at follow-up visits
over the next 6 months.
Conclusions
IRIS is a paradoxical deterioration of the clinical status
after the initiation of antiretroviral therapy. It is gener-
ally self-limiting or responds to the administration of
non-steroidal anti-inflammatory drugs or corticosteroids.
In patients with HIV and TB coinfection, paradoxical
TB-IRIS has been observed in 8-43% of HIV-infected
patients starting antiretroviral therapy while on TB
treatment [3]. The risk of TB-associated IRIS in HIV-
infected patients is higher for those with low CD4 cell
Figure 1 The immune reconstitution inflammatory syndrome in a patient with human immunodeficiency virus and Mycobacterium
tuberculosis coinfection. (A) Chest X-ray on admission. (B) Chest X-ray 3 weeks after initiation of antiretroviral therapy. (C) Computed
tomography of chest showed a large lymphadenopathy in mediastinum (arrow). (D) Tc-99 m methylene diphosphonate whole body bone scan
showed multiple increased radioactive lesions in the axial and appendicular skeleton. (E) The drained chylous left pleural effusion.
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therapy is initiated early in the course of antituberculo-
sis treatment [3]. The optimal timing for the initiation
of antiretroviral therapy after starting TB treatment
is not known. Some experts suggest that the timing
of initiation of antiretroviral therapy should be based
on CD4 cell counts and the initiation of antiretroviral
therapy should be delayed for 2 to 8 weeks in patients
with a CD4 cell count of <200 cells/μl [4]. However,
increased risk of developing further acquired immune
deficiency syndrome-defining events or death in patients
with a CD4 cell count of <100 cells/μl justify recom-
mendations to start antiretroviral therapy as soon as
possible in severely immunosuppressed HIV-infected
patients coinfected with TB [5].
Chylothorax and chylous ascites are caused by the
leakage of chyle into the pleural space and peritoneum
due to rupture or obstruction of thoracic duct, respec-
tively. Triglyceride levels >110 mg/dl, low cholesterol
level, and the presence of chylomicrons in pleural effu-
sion or ascites are diagnostic of a chylothorax or chylous
ascites [6]. Chylothorax may occur as a complication of
TB in patients with HIV infections [7]. In patients with
initial recovery after antituberculosis treatment and then
a subsequent deterioration after starting antiretroviral
therapy, the presence of a resistant strain of TB should
be excluded before establishing a diagnosis of IRIS. Rare
case reports of chylothorax or chylous ascites as a mani-
festation of Mycobacterium avium complex-associated or
TB-associated IRIS in HIV-infected patients have been
described [8-10]. In advanced HIV infection, chylothorax
may also be caused by infiltration of the thoracic duct
by Kaposi sarcoma [11]. Tissue biopsy or cultures are
required for differential diagnosis.
In our patient, chylothorax developed possibly due to
the enlargement of mediastinal lymph nodes, which
obstructed the thoracic duct flow and resulted in chyle
leakage into the pleural space. While drainage relieved
respiratory distress, failure to prevent the continual loss
of chyle can lead to life-threatening consequences
including hypovolemia, malnutrition, and electrolyte
imbalance. The administration of corticosteroid did not
halt the progressive increase in chylous pleural effusion
in our patient. With suspension of antiretroviral therapy,
continued antituberculosis therapy, corticosteroids, and
adequate drainage, our patient was treated successfully
without further sequela. This case illustrates the highly
variable manifestations of TB-associated IRIS and sug-
gests that close monitoring of clinical manifestations,
especially in the first few weeks or months of antiretro-
viral therapy initiation, is essential to minimize the
morbidity and mortality of TB-associated IRIS in
HIV-infected patients.
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